Today: 20 March 2026
Subscribe
Browse Category

Pharmaceutical Industry 16 December 2025 - 22 December 2025

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals joins the Nasdaq-100 before the U.S. market opens Dec. 22, prompting index-tracking funds to adjust positions. Shares last closed at $400.23. The company’s drug Amvuttra recently secured routine NHS use in England and Health Canada approval for ATTR cardiomyopathy. Alnylam also announced a $250 million manufacturing expansion and new FDA recognition for its technology platform.
22 December 2025
···
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

BioMarin Pharmaceutical agreed Friday to acquire Amicus Therapeutics for $14.50 per share in cash, valuing the company at $4.8 billion. FOLD shares closed near $14.18 after jumping 30% on the news. The deal is expected to close in Q2 2026, pending shareholder and regulatory approvals. Amicus disclosed a $175 million breakup fee and a June 19, 2026 outside date.
22 December 2025
····
Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen shares last traded near $327.38 as investors weighed a new FDA label expansion and U.S. drug-pricing deals announced Dec. 19. The NYSE will close early Dec. 24 and remain shut Dec. 25, thinning liquidity and increasing volatility risk. Amgen, a Dow component, remains sensitive to policy headlines and year-end positioning.
21 December 2025
···
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

BioMarin Pharmaceutical will acquire Amicus Therapeutics for $14.50 per share in cash, valuing the deal at about $4.8 billion. Amicus stock closed at $14.18 on December 19, up 30% in a day and near the offer price. The deal is expected to close in Q2 2026, pending regulatory and shareholder approval. Amicus resolved key Galafold patent litigation ahead of the announcement.
21 December 2025
···
Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer forecast 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. The company expects a $1.5 billion drop in COVID product sales and another $1.5 billion hit from patent expirations. Pfizer signed a Medicaid pricing deal with the Trump administration, warning of margin compression. Shares closed at $25.25 on Dec. 19.
21 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals reported new pediatric results for Casgevy on Dec. 6, showing all four children with severe sickle cell disease were free of vaso-occlusive crises for at least 12 months. Twelve pediatric beta thalassemia patients remained transfusion-free for at least a year. Vertex plans global regulatory filings in 2026. One TDT patient died from busulfan-related complications.
21 December 2025
··
Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences shares closed at $124.29 on Dec. 19, up 2.32%, after President Trump announced a drug pricing deal with nine major firms, including Gilead. The agreement includes Medicaid price cuts, cash-pay discounts via TrumpRx.gov, and a three-year tariff exemption tied to increased U.S. manufacturing. Gilead expects the financial impact to be manageable in 2026.
20 December 2025
··
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics shares surged 20.8% to $25.55 on December 19, 2025, amid heavy trading and technical breakout signals. The move follows recent investor conference appearances and ongoing focus on late-stage neuromuscular and cardiovascular drug programs. As of September 30, the company reported $563.3 million in cash and a Q3 net loss of $40.7 million.
20 December 2025
·
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, offering $14.50 per share. Amicus stock jumped roughly 30% to $14.18 on heavy volume, trading just below the bid as investors assess deal closure risks. Both boards approved the transaction, with closing targeted for Q2 2026 pending shareholder and regulatory approvals.
20 December 2025
·····
AbbVie Stock (ABBV) After Hours on Dec. 19, 2025: What to Know Before the Next Market Open

AbbVie Stock (ABBV) After Hours on Dec. 19, 2025: What to Know Before the Next Market Open

AbbVie shares closed at $226.82, up 1.80% Friday, then slipped a penny in after-hours trading. Trading volume surged to about 17.4 million shares as investors reacted to White House drug-pricing deals. AbbVie was not among the nine drugmakers that agreed to new pricing terms and remains in talks with the administration, according to Reuters.
20 December 2025
··
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical will acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, paying $14.50 per share—a 33% premium to Amicus’ prior close. The transaction, approved by both boards, is expected to close in Q2 2026 pending shareholder and regulatory approvals. BioMarin will fund the deal with cash and $3.7 billion in debt financing. The acquisition adds two rare-disease drugs and a Phase 3 pipeline asset.
19 December 2025
····
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer shares traded near $25.04 midday Friday after a volatile week, holding steady despite new policy headlines and a guidance reset. The company issued 2026 revenue guidance of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. Pfizer also reported positive Phase 3 results for PADCEV + Keytruda in bladder cancer.
19 December 2025
···
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK said Thursday it bought 235,000 shares on Dec. 17 as part of its ongoing buyback, bringing total repurchases since Sept. 30 to over 14 million shares. GSK’s ADR traded at $48.71 in New York, down 0.13%. The company reported 239.6 million shares now held in treasury. Earlier this week, the FDA approved GSK’s Exdensur for severe asthma.
18 December 2025
··
Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025

Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025

Pfizer shares fell 3.4% to $25.53 Wednesday after the company cut its 2025 revenue forecast to about $62 billion and issued 2026 guidance below analyst expectations. Pfizer now projects 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00. COVID-19 product sales are expected to drop to $5 billion in 2026. No share repurchases are planned for 2025 or 2026.
17 December 2025
···
Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics shares fell 9% to $79.44 on December 16, 2025, after UBS initiated coverage at Neutral with a $95 target, citing valuation concerns. The stock had surged about 75% year-to-date. No major clinical or regulatory news drove the drop. Trading volume reached approximately 1.27 million shares.
16 December 2025
···
AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie shares fell 2.2% to $222.44 as of 17:54 UTC Tuesday after Bank of America cut its price target to $233 from $248 and kept a Neutral rating. The stock had traded near the top of its 52-week range before the drop. Analysts remain divided, with consensus 12-month targets ranging from $190 to $289. No major company-specific news drove the decline.
16 December 2025
··
Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics shares traded near $22 on Dec. 16, 2025, valuing the company at roughly $2–$3 billion. The company expects to close a $291.4 million convertible debt exchange on Dec. 18, shifting debt maturities and adding $31.6 million in cash. ELEVIDYS remains under scrutiny after the FDA added a boxed warning for serious liver risks in November.
16 December 2025
·
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb shares rose 3.6% to $54.29 on December 16 after Bank of America upgraded the stock to Buy and raised its price target to $61, citing confidence in the company’s R&D pipeline. The board also increased the quarterly dividend to $0.63 per share, payable February 2, 2026, marking a 1.6% annual increase and the 17th consecutive yearly hike.
16 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb shares rose 3.6% to $54.29 Monday after Bank of America upgraded the stock to Buy and raised its price target to $61. The stock added another 0.6% in after-hours trading. Volume in extended trading reached about 1.25 million shares. Analysts cited the company’s R&D pipeline and upcoming catalysts as key drivers.
16 December 2025
··
1 … 3 4 5 6 7 8

Stock Market Today

  • Kosmos Energy (KOS) Faces Valuation Debate After 200% Surge Over Three Months
    March 20, 2026, 5:00 AM EDT. Kosmos Energy (KOS) has surged nearly 200% in 90 days, prompting investor reassessment of its valuation. The stock closed at $2.98, above a commonly cited fair value of $2.51, implying it may be overvalued based on long-term production and LNG exposure assumptions. Yet, an alternate discounted cash flow (DCF) model suggests a far higher fair value of $11.44, highlighting a 74% discount at current prices. Cost-cutting and LNG growth underpin optimism, but risks include impairments and refinancing challenges. The differing signals illuminate ongoing debate around Kosmos's growth prospects and risk profile amid a volatile energy market.
Go toTop